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• Processes acting to sense and control protein misfolding in extracellular fluids 
have previously been poorly studied. 
• Recent work has identified a small but growing family of secreted chaperones that 
are abundant in extracellular fluids. 
• These extracellular chaperones (ECs) stabilize misfolded proteins and are 
implicated in mediating their systemic clearance via receptor-mediated 
endocytosis. 
• This action operates to normally protect the human body from disease pathologies 
arising from the inappropriate misfolding and aggregation of extracellular 
proteins. 
• A better understanding of the processes that maintain extracellular proteostasis 
will open up new therapeutic opportunities for currently untreatable diseases. 
 
Future issues to be resolved for the topic 
• What are the specific receptors involved in clearing EC-misfolded protein 
complexes from extracellular fluids? 
• Which protease systems act to help clear extracellular protein deposits and do 
these synergise with ECs to safely accomplish this task? 
• Is it possible to treat disease pathologies arising from inappropriate extracellular 
protein misfolding by pharmacologically manipulating the in vivo expression 
levels of ECs (or their chaperone activities)? 
 
Mini-glossary  
• Extracellular chaperones: secreted proteins generally having a sHSP-like 
chaperone action (i.e. ATP-independent ability to stabilize misfolded proteins, 
preventing their aggregation and precipitation). 
• Proteostasis: all those processes that act to maintain the steady state levels, 
distribution and native fold of the proteome. 
 
Important acronyms  
EC  extracellular chaperone 
α2M  α2-macroglobulin 
HSP  heat shock protein 
sHSP  small heat shock protein 
Aβ  amyloid beta peptide 
AD  Alzheimer’s disease 
TTR  transthyretin 
LRP  low density lipoprotein receptor-related protein 
Apo  apolipoprotein  






There is a family of currently untreatable serious human diseases that arise from the 
inappropriate misfolding and aggregation of extracellular proteins. At present our 
understanding of mechanisms that operate to maintain proteostasis in extracellular body 
fluids is limited but has significantly advanced with the discovery of a small but growing 
family of constitutively secreted extracellular chaperones (ECs). The available evidence 
strongly suggests that these chaperones act as both sensors and disposal-mediators of 
misfolded proteins in extracellular fluids, thereby normally protecting us from disease 
pathologies. It is critically important to further increase our understanding of the 
mechanisms that operate to effect extracellular proteostasis, as this will be essential 
knowledge upon which to base the development of effective therapies for some of the 
world’s most debilitating, costly and intractable diseases. 
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1.0 Introduction  
 
The term proteostasis refers to the maintenance of the proteome as a set of individual 
proteins in a conformation, concentration and location that is required for their correct 
function (1). Proteostasis is critical for the maintenance of organismal viability and 
operates in both the intracellular and extracellular environments. By far the better 
characterized systems relate to the intracellular environment, which has been the focus of 
decades of research, leading to the identification of many important components and 
processes (see 2.0 below).  
 
The pathologies of many serious human diseases (the so-called Protein Deposition 
Diseases) are associated with the aggregation and deposition of misfolded proteins (Table 
1). Generally speaking, protein aggregates form when protein concentration exceeds 
solubility (2). Despite this, many proteins normally function at the upper edge of their 
solubilities (3). This means that any small changes in protein concentration or solubility 
(due to mutations or a change in the environment) may tip the delicate balance leading to 
aggregation and deposition. Chaperones have emerged as ubiquitous and critical players 
in proteostasis systems, where they perform a variety of roles including inhibiting protein 
aggregation, maintaining the solubility of and refolding misfolded proteins, and protein 
trafficking. As is true for proteostasis in general, knowledge of extracellular chaperones 
(ECs) has lagged well behind that of their intracellular counterparts. Nevertheless, in 
recent years it has become clear that there is a growing family of abundant proteins in the 
extracellular fluids of metazoans that share functional characteristics with the 
intracellular small heat shock proteins (sHSPs). These abundant ECs are able to bind to, 
and keep soluble, proteins that are misfolded as a result of mutations or stresses and 
inhibit their aggregation. Furthermore, the ECs are strongly implicated in clearing these 
aggregating proteins from extracellular spaces and facilitating their degradation, thereby 
playing a pivotal role in maintaining extracellular proteostasis.  
 
This review will provide a critical overview of the current understanding of the processes 
that operate in extracellular proteostasis with a particular focus on emerging knowledge 
of the ECs. A brief outline of intracellular proteostasis systems follows (2.0) because this 
provides background for the ensuing consideration of corresponding processes in the 
extracellular context. 
 
2.0  Intracellular proteostasis  
 
In order to produce properly functioning proteins the processes of transcription, RNA 
processing and transport, translation, protein folding, protein transport and ultimately 
protein degradation must be tightly regulated (1). Arguably the most important elements 
of the proteostasis machinery are the chaperones which have been defined by some as 
proteins that interact with other proteins to stabilize them or to help them acquire their 
native conformation (4). These broad functional characteristics mean that chaperones 
play a role in many cellular functions including protein folding, assembly of complexes, 
protein trafficking, protein degradation, and controlling protein aggregation and 
disaggregation. There are over a hundred chaperone genes in mammalian genomes, 
therefore no single chaperone performs all the roles identified above. Several families of 
chaperones reside inside mammalian cells and have previously been categorized on the 
basis of their molecular weights, including the sHSPs, and the HSP40, HSP60, HSP70, 
HSP90, and HSP100 families. The various chaperones have differing actions and distinct 
functional roles in protein quality control. For example, HSP70 is known to play a role 
early in the protein folding process, interacting with ribosomes, growing peptide chains 
and newly synthesized polypeptides (5). In contrast, HSP60 and HSP90 members act 
further downstream to provide an enclosed environment with hydrophobic surfaces to 
assist in the folding of specific protein clients (5, 6). Once folded, a range of 
physiological stresses can cause a protein to partially unfold or misfold. Chaperones such 
as HSP100 and the sHSPs can recognize misfolded proteins and, in co-operation with 
folding chaperones such as HSP70, allow them to refold (7).  
 
When maintenance of correct protein folding is no longer possible, cells contain a 
number of systems to remove damaged or misfolded proteins. The ubiquitin-proteasome 
system recognizes, labels and degrades stubbornly misfolded proteins. There are many 
hundreds of ubiquitin ligases (8) that through a series of highly regulated events 
covalently attach polyubiquitin chains to misfolded proteins; ubiquitinated proteins are 
subsequently transferred to the proteasome as substrates for degradation (9). In addition, 
damaged cytosolic proteins can be degraded by lysosomes via three distinct mechanisms, 
macroautophagy, microautophagy and chaperone-mediated autophagy (10). Chaperones 
are involved in controlling the movement of intractably misfolded proteins towards 
degradation machinery. For example HSP70 can, depending on the co-factors involved, 
promote folding (5), degradation through the ubiquitin-proteasome system (11), 
chaperone-mediated autophagy (12) or even actively partition misfolded proteins into 
inclusions such as the aggresome (13).  
 
Most of the current information on the function of chaperones relates to those found 
inside cells. However, chaperones are also found in other compartments, both within and 
outside cells. De novo folding of proteins destined for secretion occurs in the 
endoplasmic reticulum (ER), where a network of chaperones and other protein quality 
control mechanisms act to ensure that proteins are correctly folded before they are 
released from the cell. Synthesis of proteins destined for secretion begins on ER-
associated ribosomes. The microenvironment to which polypeptides are exposed in the 
ER is similar to that of the extracellular space; both environments contain a relatively 
high concentration of calcium ions and are oxidizing (14). Consequently, there are 
specialized chaperones and enzymes that assist in the maturation of secreted proteins. 
The ER contains members of the classical chaperone families HSP70 (BiP), HSP40, 
HSP90 and a member of the HSP100 family. Notably, there is an absence of HSP60 
family members in the ER which means that secreted proteins rely for folding exclusively 
on binding and release from folding chaperones such as BiP and the HSP90 family 
member GRP94. In the case of glycoproteins, further maturation of protein folding is 
achieved with assistance from lectin chaperones such as calnexin and calreticulin. These 
lectin chaperones work downstream of classic chaperones such as BiP through a cycle of 
binding and release which controls de-glucosylation and re-glucosylation via specific 
glucosyltransferase enzymes. The addition of glucose to the folding protein signals 
another round of binding and release, and only when the protein is fully folded will it exit 
this cycle and be released to the secretory pathway (15). Oxidoreductases of the protein 
disulfide isomerase (PDI) family also contribute to protein folding within the ER. PDIs 
catalyze the oxidation reaction required to form disulfide bonds by acting as electron 
acceptors (14); PDIs can also isomerize disulfide bonds, rearranging inappropriate 
disulfide linkages to attain native structures. 
 
The ER quality control network strives to ensure that only fully folded native proteins are 
secreted and is able to retain most misfolded proteins within the ER (16). One mechanism 
of retention is thought to involve chaperones that contain C-terminal ER retention 
sequences, such as BiP (17), physically directing bound misfolded proteins back to the 
ER. However, only structures that are recognized by ER chaperones are able to be held 
back. As a result, some proteins with “native-like” folds (e.g. some mutated forms of 
transthyretin) are able to evade the quality control system and exit to the extracellular 
space (18). Once in the extracellular space, the proteome is out of reach of the well-




3.0  Extracellular proteostasis  
 
Once in the extracellular space, secreted proteins will be bathed in large volumes of 
extracellular fluids (approximately 5 liters of blood and 10 liters of interstitial and other 
fluids in an average human). As flagged above, this environment is oxidizing and in the 
case of blood plasma especially, is subjected to ongoing shear stress during its enforced 
circulation around the body. These stresses will ensure that with time, dependent on the 
stability of individual proteins, extracellular proteins will misfold and need replacement. 
Studies from 30-40 years ago showed that misfolded forms of plasma proteins were more 
rapidly degraded than their natively folded precursors (19), hinting that a system operated 
in vivo to recognize and dispose of “damaged” extracellular proteins. Knowing what we 
do now about intracellular proteostasis, it would in fact be absolutely remarkable if there 
were not corresponding systems to deal with the potentially pathological consequences of 
extracellular protein misfolding. The known list of serious human diseases arising from 
excessive inappropriate extracellular protein misfolding and aggregation (Table 1) draws 
a line under this imperative. Importantly, however, owing to the major physical 
differences between the intracellular and extracellular environments, exactly the same 
systems cannot operate in both locations. For example, the concentration of nucleotide 
phosphates such as ATP, used by intracellular chaperones to energize protein refolding, is 
several orders of magnitude lower in extracellular fluids than inside cells (20). Thus, 
chaperone-mediated protein refolding appears a much more difficult proposition in the 
extracellular context. Similarly, although very low levels of proteasome (which also 
requires ATP) and even normally intracellular chaperones have been found in 
extracellular fluids, their concentrations are orders of magnitude lower than inside cells 
(21-23) indicating that they are unlikely to have the capacity to play any substantive role 
in protecting the organism from the challenges posed by misfolding extracellular proteins 
present at much higher levels.  
 
Then what mechanisms do operate extracellularly to protect metazoans from “aged”, 
misfolded and aggregating proteins? Theoretical options include refolding (unlikely in 
light of the above), extracellular proteolysis, and physical clearance from extracellular 
fluids for subsequent intracellular degradation (Figure 1). There is some evidence that the 
plasmin/plasminogen system may have the ability to proteolyse pre-formed extracellular 
protein deposits (24-26), although a lot more work is required here to better understand 
how major a role this might play in vivo. In addition, misfolded or aggregated proteins 
may themselves be recognized by specific receptors on the surfaces of some cells, 
however, in many cases this has been demonstrated to have subsequent pro-inflammatory 
effects (see 5.2). A body of work in recent years has identified a series of ECs that, in 
most cases, share functional similarities with the sHSPs in that they lack ATPase activity 
and cannot refold proteins (see 4.0). They are able to stabilize misfolded proteins, 
however, and keep them soluble, which not only inhibits their aggregation and toxicity 
but also facilitates their efficient delivery to receptors which may be the key to safely 
clearing these potentially dangerous species from extracellular spaces (see 5.0 & 5.3). 
 
4.0  ECs  
 
4.1 Clusterin 
Clusterin was originally named for its propensity to cause cell clustering in vitro (27), 
however, owing to its multifunctional nature it is also known by many alternative names 
including apolipoprotein J (ApoJ), SP-40,40, sulfated glycoprotein 2 and complement 
lysis inhibitor. The clusterin gene encodes a precursor polypeptide that is extensively 
glycosylated and internally cleaved to form the α and β subunits, which are linked by five 
disulphide bridges in the mature protein (28). The structure of clusterin is yet to be fully 
resolved, however, by sequence analysis it is predicted that clusterin contains three 
amphipathic α-helices and two coiled-coil α-helices (29, 30). It has also been proposed 
that the binding site on clusterin for a diverse range of hydrophobic ligands is a molten-
globule-like pocket formed by intrinsically disordered regions and amphipathic α-helices 
(31). The gamut of functions (other than chaperone) proposed for clusterin includes, but 
is not limited to, regulation of complement (32) and apoptosis (33, 34), protease 
inhibition (35), and lipid transport (30). This diversity of putative functions most likely 
reflects the ability of clusterin to bind to an extremely broad range of structurally diverse 
ligands. The concentrations of clusterin in blood plasma and cerebrospinal fluid (CSF) 
are 35-105 µg/ml and 1.2-3.6 µg/ml, respectively (36, 37). However, clusterin expression 
is up-regulated in response to many different stresses including tissue injury (38), aging 
(39), and in diseases including Alzheimer’s disease (AD) (40, 41), atherosclerosis (42), 
diabetes (42) and cancer (43). While the clusterin gene is known to encode a secretory 
signal, in some instances is appears that clusterin is retained within cells. It has been 
suggested that this is the result of the translation of a form of clusterin lacking the 
secretory signal (44). Conversely, it has been shown that full-length clusterin can be 
retrotranslocated into the cytosol in response to ER stress (45). Another form of clusterin 
directed to the nucleus is reportedly the result of alternative splicing of the clusterin gene 
(46, 47). The mechanisms by which different isoforms of clusterin may be generated is 
still highly controversial and further studies are necessary to clarify this. 
 
Clusterin is a potent sHSP-like chaperone that has been shown to inhibit stress-induced 
amorphous protein aggregation and the fibrillar aggregation of many amyloidogenic 
proteins and peptides (48-56). The structural elements responsible for the chaperone 
activity of clusterin are not yet known, however, its ability to bind to misfolded proteins 
is thought to be related to its surface hydrophobicity which is enhanced by acidic pH 
(49). The chaperone activity of clusterin is ATP-independent and in the case of 
amorphously aggregating clients, results in the formation of soluble, high molecular mass 
complexes ≥ 40 000 kDa (57). Immunodepletion of clusterin from human blood plasma 
renders plasma proteins susceptible to stress-induced precipitation (49). The near 
ubiquitous expression of clusterin, and its constitutive presence in many biological fluids, 
suggests that it performs a fundamentally important protective role in vivo. Supporting 
this, clusterin knockout mice have increased tissue damage after heat-shock (58), myosin-
induced auto-immune myocarditis (59) or post-ischemic brain injury (60). Moreover, it 
has been demonstrated that ageing clusterin knockout mice develop glomerular 
neuropathy, directly implicating clusterin in the clearance of pathological protein deposits 
(61). Additionally, clusterin is found colocalized with misfolded protein deposits in many 
diseases (Table 1).  
 
Two recent independent genome-wide association studies identified polymorphisms in 
clusterin as a strong genetic risk factor for AD (62, 63). Clusterin has been shown to 
influence amyloid formation by binding to prefibrillar aggregates rather than binding to 
the monomeric protein/peptide or mature amyloid fibrils (50-52). Depending on the ratio 
of clusterin to the fibril forming client, clusterin may either prevent further growth or 
promote elongation (51), and may either prevent or exacerbate the cytotoxicity of 
amyloidogenic peptides in vitro (51, 56, 64, 65) (see also 5.1). It has been shown that 
clusterin markedly enhances the clearance of Aβ1-42 at the blood-brain barrier (66), 
presumably via the receptor known as meglain/LRP-2 (67). However, in a mouse model 
of AD, clusterin knockout has been shown to reduce fibrillar Aβ amyloid deposition and 
neurotoxicity (68). A similar result was shown for ApoE knockout mice, however, double 
knockout of clusterin and ApoE resulted in early disease onset and a marked increase in 
Aβ peptide levels and amyloid formation (69). Thus, while the available data shows that 
clusterin can influence amyloid fibril formation and facilitate the clearance of Aβ, the 




Haptoglobin is well known for its role as a haemoglobin-binding protein and also as an 
acute phase reactant. In humans there are three major haptoglobin phenotypes (Hp1-1, 
Hp1-2 and Hp2-2) depending on the presence of two principal alleles Hp1 and Hp2, 
which encode the α1 and α2 subunits, respectively. The simplest form of haptoglobin is 
type Hp1-1, which consists of a disulfide-linked α1β dimer (70). An additional cysteine 
residue in the α2 chain allows for the formation of large complex disulfide-linked 
polymers in Hp2-1 and Hp2-2 which can form species up to 900 kDa in mass (71, 72). 
Homology with complement receptor 1 has been used to predict structural elements 
including the location of complement control protein domains, a CD163-binding region 
and the hemoglobin-binding site (73). Additionally, it has been proposed that a large 
hydrophobic region adjacent to the hemoglobin-binding site is responsible for the 
chaperone activity of haptoglobin (73, 74). 
 
Haptoglobin is found in most extracellular fluids, with concentrations of 0.3-2.0 mg/ml 
(75) and 0.5-2 µg/ml (76) in human plasma and CSF, respectively. The hepatic 
expression of haptoglobin is strongly upregulated by inflammatory mediators such as IL-
6, oncostatin M, and leukemia inhibitory factor (77). Sequestration of hemoglobin by 
haptoglobin is an important protective mechanism that reduces the amount of free 
hemoglobin and iron available to catalyze oxidative reactions (78). Other proposed roles 
for haptoglobin include, but are not limited to, regulation of cathepsin B activity (79), 
angiogenesis (80) and the immune system (81). In support of the latter, haptoglobin 
knockout mice have lower counts of mature T and B cells and display reduced adaptive 
immune responses (82). Haptoglobin phenotype has been implicated in several diseases 
including atherosclerosis where it is appears that the Hp2-2 phenotype is associated with 
increased risk and poor prognosis (reviewed in (83)). Unfortunately, studies have not yet 
examined the relationship between haptoglobin phenotype and the many protein 
deposition diseases.  
 
Like clusterin, all three haptoglobin phenotypes have been shown to inhibit stress-
induced amorphous protein aggregation of a wide range of client proteins in vitro (84, 
85), and immunodepletion of haptoglobin from human blood plasma has been shown to 
render plasma proteins susceptible to precipitation (85).  Complexation with hemoglobin 
reduces but does not abolish the chaperone activity of haptoglobin, which supports that 
the binding sites on haptoglobin for hemoglobin and misfolded client proteins are discrete 
(74, 86). By size exclusion chromatography it appears that complexes formed between 
haptoglobin and misfolded proteins are comparable in mass to those involving clusterin 
(≥ 40 000 kDa; (85)), however, little else is known about their physical characteristics. In 
contrast to clusterin, decreased pH reduces both the hydrophobicity and chaperone 
activity of hapoglobin (85). Hp2-1 has been shown to inhibit amyloid formation by a 
number of amyloidogenic proteins/peptides, however, this is currently limited to a single 
study and the effect of other haptoglobin phenotypes has not yet been investigated (86). 
Nevertheless, it appears that at substoichiometric levels Hp2-1 inhibits amyloid formation 
by forming stable complexes with client protein and preventing their elongation (86).  
 
4.3 α2-Macroglobulin (α2M) 
α2M is a multifunctional protein that is best known for its role as a broad spectrum 
protease inhibitor. X-ray crystallography data and homology modeling against 
complement component C3 have been used to predict that α2M is formed by numerous 
macroglobulin domains, an alpha helical TED (thiol ester-containing) domain, and a 
CUB (complement protein subcomponents C1r/C1s, urchin embryonic growth factor and 
bone morphogenetic protein 1) (87). The quaternary structure of α2M involves four 
identical 180 kDa chains, which covalently pair by disulfide bonds and then non-
covalently associate to form a 720 kDa tetramer (88). The ability of α2M to act as a 
protease inhibitor is due to “bait regions” which are not present in the related complement 
proteins. Upon cleavage of one or more of the bait regions by a protease, native α2M 
transitions to a more compact “activated” conformation, which migrates further than 
native α2M during native gel electrophoresis (89). During this transition, each disulfide-
bonded dimer can covalently trap a protease within a steric “cage”, tethered via an 
intramolecular thiol ester bond (90). Small nucleophiles including methylamine or 
ammonium ions can also activate α2M by directly attacking the thiol ester bond (89). The 
activation of α2M exposes a cryptic receptor recognition site for low-density lipoprotein 
receptor-related protein (LRP; also known as the α2M receptor)(90). In addition to acting 
as a protease inhibitor, it has been demonstrated that binding to α2M can enhance antigen 
presentation (91) and α2M is widely reported to act as a carrier of cytokines, growth 
factors and hormones, particularly in its activated form (92, 93). 
 
α2M is expressed by many tissues and is highly abundant in extracellular fluids. The 
concentrations of α2M in human plasma and CSF are 1.5–2 mg/ml and 1.0–3.6 mg/ml, 
respectively (90, 94). In humans, plasma levels of α2M are known to decline with age 
(95). While α2M expression is upregulated during the acute phase in rats (96), plasma 
concentrations of α2M do not increase during the acute phase in humans (97). Consistent 
with it interacting with misfolded proteins in vivo, α2M is found colocalized with 
misfolded protein deposits in many diseases (Table 1). In particular, α2M is topical in the 
field of AD owing to its ability to bind to and facilitate the clearance of Aβ via LRP (98-
100). Several independent studies have reported that polymorphism in α2M is a genetic 
risk factor for AD (101-105), however, several other studies have failed to show this 
association (106, 107). There is also vigorous debate about whether mutations in LRP are 
linked with AD (106, 108, 109). 
 
Similar to clusterin and haptoglobin, α2M has been shown to have a “holdase”-type 
chaperone activity which inhibits amorphous and fibrillar protein aggregation in vitro 
(86, 110). At present the structural elements responsible for the chaperone activity of 
α2M are not known. Investigation of the chaperone activity of α2M against stress-induced 
amorphous protein aggregation is currently limited to a single study which suggested that 
this activity was abolished by protease activation, however, α2M retained the ability to 
trap proteases after binding to misfolded proteins and α2M-protease-misfolded protein 
complexes were recognized by LRP (111). α2M has been shown to inhibit amyloid 
formation by a large number of substrates (86) and to protect cells against Aβ toxicity in 
vitro (112, 113). As for the other ECs, α2M appears to suppress amyloid formation by 
interacting with prefibrillar species that occur early in the aggregation process (86). A 
recent study showed that mildly acidic pH or 0.5 mM sodium dodecyl sulphate (which 
induce dissociation α2M tetramers into dimers), increased the binding of α2M to β2-
microglobulin (114). This report proposed that dimeric α2M may be more chaperone-
active than the tetramer, however, currently it is unknown whether α2M dimers are 
generated in humans in vivo.  
 
4.4 Caseins 
The caseins are a heterogeneous mixture of four (unrelated) phosphoproteins that include 
αS1-, αS2-, β- and κ-casein, and are the primary components of milk micelles.  All of the 
caseins lack a well-defined tertiary structure, existing as ‘natively unfolded’ proteins that 
self-associate into casein micelles, which serves as the transport vesicle for calcium to 
mammalian neonates. Both αS- (made up of αS1- and αS2- subunits) and β-casein act as 
chaperones to inhibit the stress-induced amorphous aggregation of client proteins (115), 
as well the fibrillar aggregation of Aβ (116).  Their chaperone activity is pH (117) and 
phosphorylation (118) dependent with activity being highest at the pH range typical of 
milk (i.e. 6.8 - 7.0). As for clusterin, the caseins act as ‘holdase’ chaperones by forming 
high molecular mass complexes with client proteins but do not have refolding activity 
(117, 119). Evidence of the physiological relevance of this chaperone action comes from 
findings reporting the presence of calcified amyloid-like deposits (known as corpora 
amylacea) in bovine, rat and canine mammary tissue (120-123). Moreover, when isolated 
from the other casein proteins, αS2- and κ-casein readily aggregate into amyloid fibrils 
under conditions of physiological pH and temperature (124-126). Thus, the ability of αS1- 
and β-casein to function as chaperones and associate with other proteins (including the 
other caseins) is essential for the formation and stability of casein micelles and may also 
play a role in the prevention of mammary corpora amylacea. 
 
 
4.5 Other ECs 
 
In addition to clusterin, α2M, haptoglobin and caseins, several other secreted proteins 
have been reported to have chaperone activity (summarized below). In several cases, 
analysis of the chaperone activity of these proteins is limited to a single study, thus, 
further characterization of their interactions with misfolded proteins is needed before they 
can be recognized as genuine ECs.  
 
The ε4 allele of apolipoprotein E (ApoE) is a firmly established genetic risk factor for 
late-onset AD (127). It has been demonstrated that ApoE binds to Aβ and fragments of 
amyloidogenic gelsolin and prion protein (128, 129). Binding to ApoE reportedly 
increases the β-sheet content of these peptides (129), and promotes amyloid formation 
(130). However, similar to clusterin, it appears that depending on the conditions tested, 
ApoE can also inhibit amyloid formation by influencing either the nucleation or 
elongation phases (131, 132). In mice, ApoE genotype differentially regulates the 
clearance of Aβ from the brain; complexes formed between ApoE ε2 or ApoE ε3 and Aβ 
are cleared faster than those formed between ApoE ε4 and Aβ (133, 134). Although not 
proven, this may be the critical activity that promotes AD in carriers of the ApoE4 
genotype. ApoE is found colocalized with misfolded proteins in a large number of 
diseases including with Aβ in AD (135) and Down’s Syndrome (135), with prion protein 
in spongiform encephalopathies (135), with human islet amyloid peptide in diabetes 
(136), with drusen in macular degeneration (137), and in atherosclerotic plaques (138). In 
addition to clusterin (ApoJ) and ApoE, a third apolipoprotein, ApoAI, has been reported 
to influence Aβ aggregation and toxicity in vitro (139).  
 
Albumin is by far the most abundant plasma protein, and is known to be an important 
carrier of many different molecules including Aβ (140). Several studies have reported 
that albumin inhibits stress-induced amorphous protein aggregation and amyloid 
formation in vitro (141-144). Compared to most recognized chaperones, on a molar basis 
albumin is considerably less efficient at preventing protein aggregation (57, 145, 146), 
however, given its abundance this activity may be physiologically relevant. A recent 
report suggested that the “chaperone” activity of albumin involves the formation of high 
molecular mass complexes, however, the data showed that proportionally only a very 
small amount of protein formed high molecular mass species when stressed in the 
presence of albumin (143). Further work is needed in order to determine whether albumin 
can preferential bind to misfolded proteins, or whether the chaperone-like activity of 
albumin at high concentrations is the result of weak non-specific interactions.  
 
The “secreted protein acidic and rich in cysteine” (SPARC) is a multifunctional protein 
that promotes extracellular matrix remodelling by inhibiting collagen fibrillogenesis 
(147), and acts as an intracellular chaperone for procollagen (148). Aging SPARC 
knockout mice develop cataract and abnormal collagen deposition, supporting that the 
ability of SPARC to act as a collagen chaperone is important in vivo (149, 150). In 
human patients with cataract SPARC is upregulated (151), possibly in response to stress 
(152). SPARC has been demonstrated to, at substoichiometric concentrations, prevent the 
aggregation of heat denatured alcohol dehydrogenase (153). Little is known about the 
mechanism of this activity and whether it applies to misfolded proteins more broadly, 
thus further studies are warranted.   
 
Serum amyloid P (SAP: a member of the pentraxin family) is known to bind to a diverse 
array of ligands (154-156), however, no clear biological function for this protein has yet 
been established. It has been reported that SAP has ATP-independent refolding 
chaperone activity, however, this was achieved using a very high molar excess of SAP 
and even then the recovery of heat-denatured lactate dehydrogenase activity was only 
25% (157). Nevertheless, SAP is universally found colocalized with amyloid deposits in 
disease (158), which supports that it preferentially binds to amyloidogenic proteins in 
vivo. In vitro, SAP has been shown to inhibit amyloid fibril formation and increase the 
solubility of Aβ (159), however, the association of SAP with amyloid also protects the 
fibrils from proteolytic degradation (160). Knockout of SAP expression has been shown 
to delay amyloid deposition in a mouse model of reactive amyloidosis, suggesting that it 
plays a pro-amyloidogenic role (161).  
 
Fibrinogen, a major blood protein that plays an important role in clotting, was reported as 
inhibiting stress-induced amorphous protein aggregation and amyloid formation (162). A 
later report from the same group, however, suggested that the chaperone activity is 
mediated exclusively by the αEC domain which is only present in a minor isoform of 
fibrinogen known as fibrinogen-420 (163). When present at equimolar concentrations 
fibrinogen-420 reduced the heat-induced precipitation of citrate synthase by around 50% 
(163). In comparison, purified αEC was a more potent chaperone, however, while free 
αEC can be liberated from fibrinogen-420 as a result of proteolysis, its concentration in 
vivo is likely to be only a small fraction of that of fibrinogen-420 which is normally 
around 35 µg/ml in human plasma (164). 
 
Two secreted lipocalin-type proteins, α1-acid glycoprotein and lipocalin-type 
prostaglandin D synthase (L-PGDS)/β-trace are both reported to have chaperone-like 
activity (165, 166). For L-PGDS/β-trace this has only been addressed by a single study, 
which found that (i) L-PGDS/β-trace binds to monomeric and fibrillar Aβ and is found 
colocalized with Aβ plaques in vivo, (ii) L-PGDS/β-trace inhibits Aβ fibril formation, 
and  (iii) Aβ deposition is enhanced in L-PGDS/β-trace deficient mice and decreased in 
L-PGDS/β-trace overexpressing mice compared to wild-type control mice (165). For α1-
acid glycoprotein, again the available data is limited to a single study which reported that 
α1-acid glycoprotein inhibited the in vitro aggregation of a range of proteins (166). The 
same researcher also reported in a similar one-off study that α1-antitrypsin has chaperone-
like activity (167). These latter two studies, however, lacked suitable non-chaperone 
control proteins with which to compare the effects of α1-acid glycoprotein and α1-
antitrypsin on protein aggregation. Moreover, preferential binding of α1-acid glycoprotein 
and α1-antitrypsin to misfolded proteins has not been demonstrated.  
 
 
5.0  Physiological roles of ECs  
 
ECs are proposed to patrol extracellular spaces for misfolded and aggregated proteins. 
This function has implications for the clearance of aged or damaged proteins and, 
importantly, the protection of cells and tissues from the toxic or physically disruptive 
effects of protein aggregates. Cellular contact with misfolded or aggregated proteins can 
result in direct toxic effects (see 5.1), inflammatory signaling (see 5.2) or indeed 
endocytosis and degradation (see 5.3). The outcome depends on the cell types and 
specific receptors involved, and on the actions of the ECs.  
 
5.1  Direct effects on ECs on the toxicity of protein aggregates  
 
Although all aggregate species on the amyloid forming pathway may be toxic, it has 
become apparent that smaller soluble aggregates, commonly known as oligomers, are the 
most toxic species. These oligomers, even those generated from proteins not associated 
with disease, have been shown to be more toxic than both the precursor protein/peptide 
from which they are made and the fibrils generated from them (168). The mechanism(s) 
of oligomer toxicity remain unclear, however, common structural epitopes and exposed 
hydrophobicity have been correlated with aggregate toxicity in vitro (169, 170). Very 
hydrophobic protein aggregates may interact with cell surface receptors leading to 
changes in intracellular signal transduction cascades, potentially leading to cell death 
(171) or, alternatively, insert into and then interfere directly with membrane integrity 
resulting in toxicity (172). In the context of amyloid formation, ECs interact most 
strongly with oligomers formed early in the aggregation pathway (50, 51, 86), probably 
via the exposed hydrophobic residues thought to responsible for cellular toxicity. Indeed, 
it is likely that this is a common mechanism by which a range of ECs, such as clusterin, 
α2M, haptoglobin and ApoE protect cells from misfolded or aggregated proteins (51, 173, 
174). Recent insights into the mechanism of these interactions have come from studies 
exploiting advanced microscopy techniques. Single molecule fluorescence analyses were 
used to show for the first time that clusterin forms stable, soluble complexes with a broad 
range of Aβ oligomers (ranging from dimers to 50-mers) and by doing so can inhibit 
fibrillogenesis and enhance the concentration of soluble Aβ species following 
disaggregation of pre-formed fibrils (50). Furthermore, atomic force and confocal 
microscopy was used to show that clusterin and α2M physically associate with HypF-N 
protein oligomers to induce them to form larger assemblies; this inhibited binding of the 
oligomers to cell membranes and consequently their cytotoxicity (173).  
 
However, it is important to note that the effects of ECs on the toxicity of protein 
oligomers are context-dependent. For example, clusterin and α2M were shown to enhance 
the cytotoxicity of Aβ to PC12 cells and LAN5 cells, respectively (56, 175). In contrast, 
other work has shown that clusterin and α2M can protect cells from Aβ toxicity in 
primary rat mixed neuronal cultures (64, 100). Furthermore, when Aβ was aggregated in 
the presence of clusterin at a ratio of clusterin:Aβ of 1:10, it was less toxic than Aβ alone 
to SH-SY5Y cells. However, when this same experiment was performed using a ratio of 
clusterin:Aβ of 1:500, the species formed were more toxic (51). These apparently 
opposing outcomes probably arise as a result of stoichiometry-dependent differential 
effects of ECs on oligomer structure. When present at relatively high ratios of 
chaperone:client, the ECs may be able to effectively mask most of the hydrophobicity 
exposed on the oligomers (thereby reducing their toxicity). In contrast, when present at 
lower ratios of chaperone:client, the ECs may structurally stabilize the oligomers, leading 
to the generation of more oligomers, but be present at insufficient levels to shield all the 
hydrophobic regions exposed on the oligomers.  
 
5.2  Anti-inflammatory effects of ECs There are many reports describing the effects of 
clusterin, haptoglobin and α2M on the immune system (59, 176-180). Some of these, such 
as the ability of α2M to enhance antigen presentation (91) and haptoglobin-facilitated 
clearance of hemoglobin (180), clearly fall outside of the scope of this review and as 
such, will not be discussed here. With direct relevance to their function as ECs, a large 
number of recent studies have now shown that amyloidogenic peptides and aggregates of 
misfolded proteins are potently immunostimulatory (reviewed in (181)). Moreover, it has 
been suggested that hydrophobicity is universally recognized as a damage-associated 
pattern by the innate immune system (182). The rationale for this hypothesis comes in 
part from the fact that innate immune systems receptors such as toll-like receptors (TLRs) 
and scavenger receptors are highly promiscuous and bind to a very large number of 
ligands. These ligands are structurally diverse, however, most share the trait of normally 
being either hydrophobic or prone to exposing large areas of hydrophobicity when they 
are damaged or modified (e.g. bacterial lipopolysacharride (183)). Furthermore, it has 
recently been shown that when exposed to gold nanoparticles the expression of pro-
inflammatory cytokines by splenocytes correlates with the surface hydrophobicity of 
these particles (184).	   
 
Protein misfolding is accompanied by chronic inflammatory pathology in many diseases 
including AD, prion disease, arthritis, macular degeneration and atherosclerosis. Reports 
describing the in vitro activation of microglia and astrocytes via stimulation of scavenger 
receptors and TLRs by amyloidogenic peptides are too numerous to address individually 
here, therefore, just a few examples will be discussed (reviewed in (181)). Fibrillar Aβ 
reportedly interacts with an ensemble of innate immune receptors including SR-AI, 
CD36, CD14, TLR-2, TLR-4 and formyl peptide receptor 2 (185-187), the net effect 
being upregulation of pro-inflammatory genes such as iNOS, COX2 and TNFα, and the 
initiation of respiratory burst (187, 188). A role for amyloids in platelet activation has 
also been suggested and CD36 and von Willebrand factor receptor glycoprotein Ibα were 
implicated in this process (189). Direct comparison of Aβ oligomers and Aβ fibrils 
suggests that small oligomers of Aβ are more potent stimulators of microglia and 
astrocytes (187, 190, 191), and supports the hypothesis that the hydrophobicity of the 
agonist is important. The ability of misfolded proteins to stimulate pro-inflammatory 
responses does not appear to be limited to amyloid, for example amorphous aggregates 
formed by the denaturation of large globular proteins have been shown to stimulate nitric 
oxide and superoxide production in macrophages (192). This activity was attributed to 
interaction of the aggregates with β1β2 integrins, MAC-1 and receptor for advanced 
glycation end products (RAGE) (192, 193).  
 
Taken together the findings of the aforementioned studies strongly support that misfolded 
proteins are inherently immunostimulatory and this may be an important mechanism by 
which they contribute to the pathology of disease. Considering that inflammation is a 
state in which numerous stresses including heat and the concentration of free radicals are 
increased, it is possible that misfolded proteins and inflammation together generate a self-
perpetuating cycle. Although the anti-inflammatory actions of the ECs may involve 
several mechanisms, close examination of their biological activities supports that at least 
some of their immunomodulatory effects are linked to their inherent property to bind and 
mask areas of exposed hydrophobicity on molecules. For example, the binding of α2M to 
cytokines, which is currently considered a major mechanism by which it exerts 
immunomodulatory effects, is driven by hydrophobic interactions in many cases (92, 93, 
194). Similarly, hydrophobic interactions are central to the interactions of clusterin with 
the complement system (32). Thus, it is tempting to speculate that an additional, yet to be 
characterized immunomodulatory activity of ECs, may be the direct result of their ability 
to mask regions of exposed hydrophobicity on misfolded proteins and other ligands, 
thereby reducing their ability to participate in pro-inflammatory signaling.  
 
5.3  EC-mediated clearance of protein aggregates 
In addition to directly shielding cells from hydrophobic protein aggregates, ECs may also 
protect cells by playing an important role in physically clearing misfolded proteins from 
extracellular fluids. Although receptors that can recognize and directly bind to misfolded 
or aggregated proteins have been identified, continued aggregation will result in the 
formation of insoluble deposits which have restricted access to cell surface receptors and 
that may persist in the body for extended periods. Additionally, there is evidence that the 
recognition of misfolded proteins by receptors may in fact contribute to their pathological 
effects (see above). The formation of complexes between ECs and misfolded proteins 
inhibits further aggregation of the latter, maintains them in solution and enhances the 
efficiency with which they are delivered to cell surface receptors for clearance. For 
example, SH-SY5Y cells expressing the α2M receptor (LRP) are more resistant to Aβ  
toxicity in the presence of α2M than cells that do not (175). In this context, the protection 
afforded by LRP expression could be inhibited with receptor-associated protein (a ligand 
that inhibits binding of species to LRP), further supporting the notion that internalization 
of α2M-Aβ complexes is cytoprotective. Along similar lines, in the presence of α2M, Aβ 
was cytotoxic to LRP-negative LAN5 cells but not when the LAN5 cells were transfected 
with LRP (175). When Aβ is added into AD patient CSF, it is more toxic to SH-SY5Y 
cells than Aβ added into control CSF; adding ECs (clusterin, α2M and haptoglobin) 
suppresses this toxicity and this effect coincides with a more efficient cellular uptake of 
Aβ (112). Furthermore, it has been demonstrated that clusterin-Aβ complexes bind to the 
receptor megalin on the surface of mouse teratocarcinoma F9 cells, and are subsequently 
internalized, via receptor mediated endocytosis, transported to lysosomes and degraded 
(195). Likewise, complexes formed between protease-activated α2M and Aβ bind LRP 
and are internalized in U87 cells and subsequently degraded (99).  Importantly, in vivo 
studies also strongly support that clusterin and α2M facilitate the clearance of Aβ via 
interactions with lipoprotein receptors (66, 196). In a rat model, complexes formed 
between clusterin and misfolded client proteins are quickly and specifically taken up by 
liver hepatocytes and degraded within lysosomes (197). This uptake can be delayed by in 
vivo injection of fucoidin, an inhibitor of scavenger receptors, implicating these in 
receptor-mediated endocytosis of the chaperone-client complexes. This may reflect a 
process in which protein aggregates are maintained in solution in complex with ECs until 
cell surface pattern recognition receptors bind to hydrophobic or misfolded protein 
epitopes exposed on the complexes and mediate their cellular uptake. Scavenger 
receptors also reportedly facilitate the uptake of methylamine-activated α2M by liver 
endothelial and kupffer cells (198), however, previous studies have not addressed 
whether this is also a pathway by which α2M facilitates the clearance of misfolded client 
proteins. It is well known that human macrophages use the CD163 receptor to bind and 
internalize haptoglobin-hemoglobin complexes for subsequent degradation (199); 
however, the identity of receptor(s) that may function in clearing haptoglobin-misfolded 
protein complexes is not yet known. Taken together, the available evidence suggests that 
ECs protect cells from toxic and pro-inflammatory protein aggregates both by masking 
regions of exposed hydrophobicity on them and by promoting their receptor-mediated 
cellular uptake and degradation (Figure 2).  An intriguing question which requires further 
investigation is whether extracellular proteolysis systems (e.g. plasminogen/plasmin) 
might synergize with ECs to digest and clear insoluble extracellular protein deposits. 
Although much remains to be done to identify all the relevant cell surface receptors 
involved in the systemic clearance of EC-misfolded protein complexes, scavenger and 
lipoprotein receptors are strongly implicated in clearing complexes incorporating 
clusterin and α2M. 
 
 
6.0 Therapeutic opportunities 
 
Available treatments for extracellular protein deposition diseases are currently limited to 
reducing their symptoms. Without effective prophylactics or cures, the already heavy 
burden of diseases such as AD, macular degeneration and arthritis will continue to grow 
within our aging society. Thus, there is an urgent need to better understand the 
fundamental biological systems that normally protect the body from accumulating 
misfolded proteins in extracellular spaces. Many amyloidoses result from the 
accumulation of a single protein. To stem the production of this protein would provide a 
first line of defense against its accumulation. In cases where the disease-relevant protein 
is primarily synthesized by the liver, organ transplantation is a drastic but effective means 
by which to control the disease. Currently, liver transplant is most common for the 
treatment of transthyretin (TTR) related familial amyloidosis (200), and has been 
successfully used to treat other forms of amyloidosis including those resulting from 
mutation in fibrinogen α-chain or lysozyme (201, 202). Nevertheless, surgery of this kind 
carries serious risk and unless taken as a preemptive measure, damage to other organs 
may already be severe at the time of transplantation. Moreover, the disease will continue 
to progress if the amyloidogenic protein is expressed by other tissues. Suppression of the 
expression of amyloid forming proteins using antisense oligonucleotides or small 
interfering RNA are promising new therapeutic strategies (203, 204). Treatment of this 
kind, however, is suitable only if knockout of the target does not negatively impact upon 
overall organismal health, such as is the case for TTR (205), but not other examples such 
as the amyloid precursor protein (APP) (206). Rather than target the expression of APP, 
an alternative strategy to prevent/treat AD is to reduce the expression of the enzymes 
responsible for the production of Aβ1-42 (207), since is well known that Aβ1-42 has a 
higher tendency to aggregate compared to Aβ1-40 peptide.  
 
A variety of small molecules are known to inhibit the aggregation/fibrillogenesis of 
disease-relevant proteins in vitro (reviewed in (208)). Unfortunately, clinical use of these 
compounds is not possible due to their lack of specificity, the high concentrations 
required to elicit an effect and their low tolerability in vivo. Therefore, current research is 
focused on identifying molecules that specifically target amyloidogenic proteins and 
disrupt their aggregation. A successful example of this is the drug Tafamadis, which has 
recently been approved by the European Medicines Agency (209). Tafamadis inhibits 
amyloid formation by stabilizing the tetrameric form of TTR, the dissociation of which 
into monomers is the rate-limiting step in TTR amyloid formation (210). Promising novel 
peptide-based strategies are also currently under development, including “β-sheet 
breakers”, which have been shown to reduce amyloid deposition in mouse models of AD 
(211). A major limitation of anti-aggregation strategies is the lack of knowledge 
surrounding precisely which of the aggregated species are responsible for disease 
(reviewed in (212)). This limitation may be overcome by the development of therapeutics 
that not only influence the aggregation of misfolded proteins, but also efficiently target 
them for disposal. Importantly, a recent study comparing AD patients with normal 
controls showed that the levels of Aβ (1-40 and 1-42) production were the same in both 
groups but that the clearance of Aβ was significantly decreased in AD patients, strongly 
implicating impaired Aβ clearance in AD pathogenesis (213). Immunotherapy has been 
investigated as a means to increase the clearance of disease-relevant proteins/peptides. 
Active immunization using Aβ1-42 peptide and passive immunization using antibodies 
raised against Aβ1-42 have both been demonstrated to reduce Aβ deposition and cognitive 
decline in mice (214, 215). An early clinical trial using full length Aβ1-42 as the 
immunogen in humans was halted due to the incidence of meningoencephalitis in a small 
proportion of the patients (216), nevertheless, long-term follow up of the patients from 
this trial showed significantly less cognitive decline and brain volume loss in those 
patients who had generated an antibody response during the trial compared to controls 
(217). The results of a more recent clinical trial suggest that side effects such as 
meningoencephalitis may be avoided by using a shorter fragment of Aβ1-42 as the 
immunogen, rather than the full length peptide (218). 
 
The discovery of ECs is an important landmark in our developing understanding of the 
mechanisms comprising extracellular proteostasis. Further characterization of the 
activities of the ECs, in particular their ability to facilitate the clearance of misfolded 
extracellular proteins (see section 5.3), will open up new avenues for the development of 
novel therapies. Exogenous administration of the normally intracellular sHsp αB-
crystallin is protective in animal models of acute ischemic and autoimmune disease (219-
222). The effect of αB-crystallin is potently anti-inflammatory and it has been suggested 
that this is directly related to its ability to sequester misfolded proteins (223). Considering 
that the activity of the ECs is similar to that of αB-crystallin, it is tempting to speculate 
that increasing their extracellular concentrations may have a similar therapeutic effect. 
Given that they are normally secreted it may be possible to increase the concentrations of 
ECs by administration directly in to the blood stream, however entry to the nervous 
system would be problematic due to the blood brain barrier. Alternatively, increases in 
EC concentration could be achieved by targeting regulatory elements in the promoters 
responsible for their expression (224-227). However, the overexpression of clusterin been 
implicated in cancer pathogenesis and protection from chemotherapy drugs (43), thus, the 
possible side effects of the upregulation of ECs needs to be carefully evaluated. As 
outlined above (see section 5.1 and 5.2) there is strong evidence indicating that ECs 
reduce the toxicity of misfolded proteins, depending on the ratio of EC to amyloid 
forming protein, and the presence (or not) of specific receptors to promote clearance of 
complexes formed between the two molecules (51). Therefore, when targeting EC 
expression as a therapeutic strategy, it is important to consider the pathways by which 
chaperone-misfolded client protein complexes are cleared. For instance, in AD, 
downregulation of LRP at the blood brain barrier is coupled with increased expression of 
several LRP ligands (228-231), suggesting that accumulation of Aβ may in part be the 
result of overwhelming of LRP. In this scenario, increasing the concentration of α2M may 
not have any therapeutic benefit unless the expression of LRP is also increased. A final 
intriguing possibility yet to be explored is to pharmacologically manipulate the in vivo 
chaperone activity of endogenous ECs. 
  
7.0 Conclusions  
Proteostasis is critical to maintain organismal viability, and logically must operate in all 
body spaces. Knowledge of those processes that achieve this in extracellular body spaces 
are only now being identified but are likely to depend heavily upon the involvement of 
recently discovered, constitutively secreted ECs. The available evidence strongly 
suggests that these chaperones act as both sensors and disposal-mediators of misfolded 
proteins in extracellular fluids. Their actions are likely to normally defend the human 
body from a range of serious diseases arising from inappropriate extracellular protein 
aggregation and deposition. It is therefore critically important to advance knowledge of 
ECs and how they integrate with various molecular and cellular mechanisms to effect 
extracellular proteostasis. This is essential if we are to one day identify effective therapies 
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Table 1. Some examples of extracellular protein deposition disease, the protein/peptide 
implicated in their pathology and the ECs found co-localized with these deposits.  
 
Disease Aggregating protein/peptide Co-localized chaperones 















Atherosclerosis ApoB-100 Clusterin (237) α2M (238) 
Familial British 
dementia ABri Clusterin (239) 
Familial Danish 
Dementia ADan Clusterin (240) 
Down’s syndrome Aβ Clusterin (241) 
Type II Diabetes Human Islet Amyloid Peptide Clusterin (242) 
Hemodialysis-related 




Transthyretin  Clusterin (244) 
Systemic Amyloidosis Immunoglobulin light chain Clusterin (245) 
Corneal Dystrophies Keratoepithelin Clusterin (246) 
Glomerulonephritis 
 
IgA Haptoglobin (247) 
Corpora amylacea 
β-lactoglobulin, α-
lactalbumin and other 
undetermined proteins 




Figure 1. Major elements of extracellular proteostasis. Proteins have undergone 
rigorous quality control before they are secreted, generally in a natively folded state. 
Once in the extracellular environment, they encounter a variety of stresses which can 
cause them to partially unfold and populate misfolded states. Misfolded proteins can 
aggregate into soluble oligomers and subsequently into insoluble fibrillar or amorphous 
aggregates. Extracellular chaperones (ECs) are known to form stable complexes with 
misfolded protein species, including misfolded monomers and oligomers. These 
complexes maintain misfolded proteins in solution and facilitate their clearance from 
extracellular fluids via receptor mediated endocytosis (RME) and degradation in 
lysosomes. In some cases misfolded, modified or aggregated proteins can also be cleared 
via RME without the involvement of ECs; large insoluble aggregates must be 
phagocytosed. Furthermore, extracellular proteases such as plasmin may be activated by 
protein aggregates and subsequently degrade them.  
 
Figure 2.  Model for the effects of ECs on toxicity and inflammation driven by 
misfolded extracellular proteins. Misfolded proteins and aggregates can be toxic to 
cells by a variety of mechanisms including disruption of membrane integrity, inducing 
changes in intracellular signal transduction cascades, and indirectly by eliciting pro-
inflammatory signaling in immune cells Extracellular chaperones (ECs) are likely to be 
cytoprotective because of their ability to shield hydrophobic residues on the surfaces of 
these species that can mediate interactions with cell membranes and receptors. The 
actions of the ECs also inhibit the formation of larger aggregates and facilitate their 
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